Ajanta Out-Licenses Product to Taiwan Firm (India)
This article was originally published in PharmAsia News
India-based drug maker Ajanta is currently bucking the market trend of in-licensing foreign pharmaceuticals for production in India. Instead, Ajanta is out-licensing its anti-scar drug Vanzia to Taiwan-based Orient Europharma. Under the contract the drug will be marketed by Orient in Singapore, Macau, Hong Kong, and Malaysia, as well as Taiwan. Ajanta has also agreed to sell manufacturing technology to the drug in exchange for an up-front cash payout, and further revenue sharing. (Click here for more
You may also be interested in...
The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.
Strides is expanding its presence in synthetic injectables via a new company, SteriScience, while keeping its biologics injectables business under Stelis. A head start with existing IP assets and those from a new joint venture with Brooks Labs will enable the fledgling firm to file its first ANDA in fiscal 2021, with break-even foreseen in two years.